Intersect ENT, Inc. (XENT) Forecasted to Earn Q1 2018 Earnings of ($0.08) Per Share
Intersect ENT, Inc. (NASDAQ:XENT) – Stock analysts at Leerink Swann issued their Q1 2018 earnings per share estimates for shares of Intersect ENT in a note issued to investors on Monday. Leerink Swann analyst R. Newitter expects that the medical equipment provider will post earnings per share of ($0.08) for the quarter. Leerink Swann also issued estimates for Intersect ENT’s Q4 2018 earnings at ($0.14) EPS.
Intersect ENT (NASDAQ:XENT) last posted its quarterly earnings data on Tuesday, August 1st. The medical equipment provider reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.11. Intersect ENT had a negative return on equity of 17.60% and a negative net margin of 22.94%. The company had revenue of $24.00 million during the quarter, compared to analysts’ expectations of $22.62 million. During the same quarter in the prior year, the business earned ($0.21) earnings per share. Intersect ENT’s revenue for the quarter was up 24.4% compared to the same quarter last year.
COPYRIGHT VIOLATION WARNING: This news story was posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/18/intersect-ent-inc-xent-forecasted-to-earn-q1-2018-earnings-of-0-08-per-share.html.
Several other analysts have also commented on XENT. Bank of America Corporation lifted their price target on shares of Intersect ENT from $33.00 to $40.00 and gave the company a “buy” rating in a research report on Monday, September 11th. Zacks Investment Research downgraded shares of Intersect ENT from a “hold” rating to a “sell” rating in a research note on Wednesday, July 5th. Canaccord Genuity boosted their target price on shares of Intersect ENT from $32.00 to $37.00 and gave the stock a “buy” rating in a research note on Wednesday, September 13th. BidaskClub downgraded shares of Intersect ENT from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 25th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and issued a $35.00 target price on shares of Intersect ENT in a report on Tuesday, August 22nd. Four research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Intersect ENT has an average rating of “Buy” and a consensus price target of $27.70.
Intersect ENT (NASDAQ XENT) traded up 1.05% during trading on Wednesday, hitting $28.95. The stock had a trading volume of 21,688 shares. The company’s market cap is $845.02 million. The firm’s 50-day moving average price is $30.18 and its 200-day moving average price is $26.24. Intersect ENT has a 52-week low of $7.65 and a 52-week high of $33.25.
In other news, COO Richard E. Kaufman sold 12,500 shares of Intersect ENT stock in a transaction dated Tuesday, July 25th. The shares were sold at an average price of $28.25, for a total value of $353,125.00. Following the completion of the transaction, the chief operating officer now directly owns 169,821 shares of the company’s stock, valued at approximately $4,797,443.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Lisa D. Earnhardt sold 20,000 shares of Intersect ENT stock in a transaction dated Monday, October 16th. The shares were sold at an average price of $28.37, for a total transaction of $567,400.00. The disclosure for this sale can be found here. Insiders sold a total of 147,063 shares of company stock valued at $4,368,029 over the last ninety days. Company insiders own 13.70% of the company’s stock.
A number of institutional investors have recently bought and sold shares of XENT. Nationwide Fund Advisors boosted its stake in Intersect ENT by 8.8% during the 1st quarter. Nationwide Fund Advisors now owns 38,698 shares of the medical equipment provider’s stock valued at $664,000 after purchasing an additional 3,134 shares during the period. Russell Investments Group Ltd. boosted its stake in Intersect ENT by 11.4% during the 1st quarter. Russell Investments Group Ltd. now owns 35,124 shares of the medical equipment provider’s stock valued at $602,000 after purchasing an additional 3,594 shares during the period. Bank of New York Mellon Corp boosted its stake in Intersect ENT by 10.8% during the 1st quarter. Bank of New York Mellon Corp now owns 150,540 shares of the medical equipment provider’s stock valued at $2,582,000 after purchasing an additional 14,659 shares during the period. American International Group Inc. boosted its stake in Intersect ENT by 7.1% during the 1st quarter. American International Group Inc. now owns 15,704 shares of the medical equipment provider’s stock valued at $269,000 after purchasing an additional 1,037 shares during the period. Finally, Cornerstone Capital Management Holdings LLC. boosted its stake in Intersect ENT by 109.1% during the 1st quarter. Cornerstone Capital Management Holdings LLC. now owns 11,500 shares of the medical equipment provider’s stock valued at $196,000 after purchasing an additional 6,000 shares during the period. 83.12% of the stock is owned by hedge funds and other institutional investors.
Intersect ENT Company Profile
Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.
Receive News & Ratings for Intersect ENT Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT Inc. and related companies with MarketBeat.com's FREE daily email newsletter.